Oculogica

Oculogica operates at the intersection of medical devices, concussion diagnostics, neuroscience, and digital health. Its primary differentiation is an objective, baseline-free eye-tracking assessment: EyeBOX is described as a four-minute, non-invasive test that requires no patient-specific baseline or calibration and is FDA-cleared as an aid in concussion diagnosis. That positioning addresses a practical limitation of many concussion assessments, which can depend heavily on symptoms, patient reporting, or pre-injury baseline data. The company also identifies SNAP as a rapid sideline screening tool, extending its product scope beyond clinic-based assessment. As a result, Oculogica’s relative market share cannot be determined. Its seven published research papers, 11 granted patents, and clinical-study activity indicate an evidence- and IP-oriented strategy, while the 2022 Minnetronix relationship suggests an effort to convert the technology into a scalable commercial device.

Oculogica’s trajectory shows a transition from early research and seed financing toward regulated product commercialization. The company was founded in 2013 and raised three disclosed seed rounds between 2014 and 2016 totaling approximately $3.51 million, followed by an angel round in 2017 with no public amount. Its 2019 Series A raised $8.18 million, led by TitletownTech, and was followed by a $2 million grant in 2021. Product commercialization became more visible in 2022, when Oculogica announced the EyeBOX launch, worked with Minnetronix on device launch activities, and raised $4.05 million in venture financing alongside undisclosed debt financing. A further $7.57 million venture round in May 2024 brought cumulative funding to $25.31 million. Clinical publication in 2023 and additional patent activity in 2024 support continued product validation and defensibility.